Esphera SynBio, a synthetic biology platform is reprogramming the human body’s own communication system to deliver new cancer and infectious disease therapeutics, a solution with the power to impact many lives.
The company has gained the attention of many sector leaders. Within a year, Esphera SynBio closed a $3 million seed round from GKCC and FACIT and successfully filed five patents. However, the team’s immediate challenge was a strategic one: capturing the pre-clinical data needed to de-risk their solution and open up key opportunities in the future.
The technology behind Esphera SynBio’s solution
Co-founded by a team of serial entrepreneurs working together from Hamilton and Ottawa, Esphera’s innovation lies in its core technology, which leverages exosomes. Imagine these tiny vesicles that all cells use for communication as the body’s natural “cell phones.”.
The company’s platform innovates by manipulating this biology, acting like a virus to seamlessly insert its therapeutic function directly into the body’s processes.
Instead of complex, time-consuming outside the body manufacturing, Esphera’s system delivers a transgene that programs a cell to produce modified, therapeutic exosomes. These vesicles are engineered to target a specific cell type, like an immune cell, and generate the final, potent medicine only where it is needed. This manufacturing-within-the-body approach allows the company to get past historical manufacturing limitations in the field.
Dr. Brian Lichty, Co-founder and CEO of Esphera SynBio, shares, “Exosomes are nature’s perfect delivery system. Our breakthrough isn’t just about what we deliver, but how elegantly we’re programming the body itself to be the manufacturer. This shifts the entire paradigm for therapeutic delivery.”
Working with Innovation Factory and next steps
Esphera SynBio’s journey to secure its next milestone required leveraging both capital and scientific expertise. The team was looking for non-dilutive support to fund critical pre-clinical testing on humanized mice, generating the data required for a clinical trial and their upcoming funding round.
“For deep-tech ventures like ours, securing early patents and a seed round is just the start. The Series A hinges entirely on solid pre-clinical data—and accessing non-dilutive capital to fund that critical testing was the immediate, most vital priority,” says Dr. Lichty.
The team was recommended to apply to Innovation Factory’s SOPHIE program (Southern Ontario Pharmaceutical and Health Innovation Ecosystem). Funded by a Government of Canada investment through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), SOPHIE helps technology companies develop, test, and commercialize innovative healthcare solutions. The program provided the necessary funding and helped establish a collaborative relationship with McMaster University.
As a leading research institution, McMaster provided the essential expertise and facilities the team needed to grow and scale. “Partnering with McMaster, right here in the Hamilton ecosystem, wasn’t just convenient; it was strategic. We’re leveraging world-class facilities and the specific expertise of researchers who already understand our IP. That level of integration significantly accelerated our timeline,” explains Dr. Lichty.
The Esphera team is leveraging spaces like McMaster’s Fitzhenry Vector Laboratory and the Ottawa Hospital’s Biotherapeutics Manufacturing Centre, focusing on growing within the Canadian ecosystem.
Accelerating growth and a clear clinical path
By accessing the necessary data and expertise through SOPHIE and its partners, Esphera SynBio has accelerated its path to scale, and here’s how:
- Fundraising: The data generated is the essential component needed to unlock its planned $38-million Series A in Q1/Q2 2026, and the team is on track to achieve that milestone.
- Team Expansion: The momentum will allow the company to grow its team from 11 to 20 employees to support dual R&D locations in Hamilton and Ottawa.
- Clinical Goal: The company is now focused on moving its cancer vaccine candidate into a Phase 1 trial by Q2 2027, bringing its solutions closer to patients who need it the most.
- Strategic Partnership: As Esphera grows its tech and team, the start-up is also hoping to secure partnership opportunities with pharmaceutical companies, like the one with the CQDM Quantum Leap program, to enhance the next-generation mRNA vaccines.
Esphera SynBio’s journey is a great reminder of how strategic ecosystem support and funding can accelerate the pathway from an idea to a tangible, real-world product. By leveraging programs like SOPHIE, Esphera is positioned to make a significant impact on the future of healthcare.
Interested in learning about Innovation Factory’s SOPHIE program? Connect with us to find out more.